WallStSmart

Abbott Laboratories (ABT)vsGE HealthCare Technologies Inc. (GEHC)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 127% more annual revenue ($48.23B vs $21.27B). ABT leads profitability with a 9.8% profit margin vs 9.3%. ABT appears more attractively valued with a PEG of 1.52. GEHC earns a higher WallStSmart Score of 65/100 (C+).

ABT

Buy

52

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

GEHC

Buy

65

out of 100

Grade: C+

Growth: 6.0Profit: 6.5Value: 5.7Quality: 4.5
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-38.8%)

Margin of Safety

-38.8%

Fair Value

$76.51

Current Price

$109.41

$32.90 premium

UndervaluedFair: $76.51Overvalued

Intrinsic value data unavailable for GEHC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$184.98B9/10

Large-cap with strong market position

Free Cash FlowQuality
$2.09B8/10

Generating 2.1B in free cash flow

GEHC1 strengths · Avg: 8.0/10
P/E RatioValuation
16.3x8/10

Attractively priced relative to earnings

Areas to Watch

ABT3 concerns · Avg: 3.3/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
39.5x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-43.7%2/10

Earnings declined 43.7%

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.774/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Free Cash FlowQuality
$-617.00M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Free Cash Flow. Revenue growth of 14.5% demonstrates continued momentum.

Bull Case : GEHC

The strongest argument for GEHC centers on P/E Ratio.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, Free Cash Flow.

Key Dynamics to Monitor

GEHC carries more volatility with a beta of 0.85 — expect wider price swings.

ABT is growing revenue faster at 14.5% — sustainability is the question.

ABT generates stronger free cash flow (2.1B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

GEHC scores higher overall (65/100 vs 52/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?